Admilparant

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameAdmilparant
Drug Alias NameBMS-986278BMS-986278-01
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLysophosphatidic acid receptor Edg-2 antagonists
TargetsLysophosphatidic acid receptor Edg-2
Therapy Area/IndicationsKidney Failure, ChronicRenal InsufficiencyIdiopathic Pulmonary Fibrosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[35] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdBristol-Myers Squibb Company
Inactive CompaniesN/A
Active IndicationsKidney Failure, ChronicRenal InsufficiencyIdiopathic Pulmonary Fibrosis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A